Streetbeat News

Analyst Ratings

TMCI

Truist Securities analyst Richard Newitter has maintained a Buy rating on Treace Medical Concepts (NASDAQ:TMCI) and increased the price target from $12 to $16.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 3:13 pm

TFX

Truist Securities analyst Richard Newitter has maintained a Hold rating on Teleflex (NYSE:TFX) and increased the price target from $221 to $270.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 3:11 pm

LITE

Lumentum Holdings' stock (LITE) is trading higher following an upgrade from Hold to Buy by Craig-Hallum.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 3:11 pm

SYK

Truist Securities analyst Richard Newitter has maintained a Hold rating on Stryker (NYSE:SYK) and increased the price target from $300 to $320.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 3:11 pm

PAYX

JP Morgan analyst Tien-Tsin Huang has maintained an Underweight rating on Paychex (NASDAQ:PAYX) and reduced the price target from $134 to $126.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 3:10 pm

BHVN

Biohaven's stock (BHVN) is trading higher following a Buy rating initiation and a $50 price target from HC Wainwright & Co.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 3:09 pm

SIBN

Truist Securities analyst David Rescott has reaffirmed a Buy rating on SI-BONE (NASDAQ:SIBN) and increased the price target from $25 to $26.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 3:09 pm

NKE

JP Morgan analyst Matthew Korn has maintained an Overweight rating on Nike (NYSE:NKE) but has reduced the price target from $139 to $128.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 3:08 pm

RLJ

Truist Securities analyst Gregory Miller has reaffirmed a Buy rating on RLJ Lodging (NYSE:RLJ) and increased the price target from $13 to $14.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 3:07 pm

DOC

Truist Securities analyst Michael Lewis has maintained a Hold rating on Physicians Realty Trust (NYSE:DOC) but has reduced the price target from $15 to $14.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 3:06 pm